natgillin/translations-raw huggingface dataset:
An ex-vivo or in-vitro method for obtaining translation of at least one protein of interest in a human or animal cell comprising: repeatedly or continuously introducing into the cell an RNA composition comprising mRNA that encodes the at least one protein of interest, wherein said RNA composition has been treated with RNaseIII in a buffered aqueous solution comprising magnesium cations at a concentration of about 1-4 mM and a salt providing an ionic strength equivalent to at least about 50-300 mM potassium acetate or potassium glutamate, and culturing the cell under conditions wherein the cell survives and grows, and wherein the mRNA is translated. 
Obrađeni sastav ribonukleinske kiseline (dalje u tekstu:RNA), koji sadrži in vitro sintetiziranu ssRNA ili mRNA, gdje je manje od 0,01%, poželjno manje od 0,001%, nadalje, poželjno manje od 0,0002% mase RNA u spomenutom tretiranom sastavu RNA dvolančana RNA (dsRNA) veličine veće od oko 40 duljina parova; pri čemu je navedeni obrađeni sastav ribonukleinske kiseline dobiven obradom ssRNA sintetiziranom in vitro s proteinom specifičnim za dsRNA endoribonukleaza III u puferiranoj vodenoj otopini koja sadrži katione magnezija u koncentraciji od oko 1-4 mM, te soli koja daje ionsku snagu ekvivalentnu barem oko 50 mM kalijevog acetata ili kalijevog glutamata.
R6-NCO (IV) wherein R6 represents C1-4 alkyl group, phenyl or optionally substituted phenyl group with an amine of formula (III): wherein R1 represents hydrogen atom or C1-4 alkyl group, R2 represents hydrogen atom or C1-4 alkyl group, and, where appropriate, separating the enantiomers and/or diastereomers, and/or cis- and/or trans-isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
pri čemu predstavlja vodikov atom ili C1-4 alkil skupinu, predstavlja vodikov atom ili C1-4 alkil skupinu, i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (I), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formule (I).
Further inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis including, e.g., aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis. 
Daljnje upalne ili opstrukcijske bolesti dišnih puteva na koje se predloženi izum može primijeniti uključuju pneumokoniozu (upalnu, najčešće profesionalnu bolcst pluća, koja je često popraćena s opstrukcijom dišnih puteva, bilo kronična ili akutna, i uzrokovana s ponovljenim udisanjem prašine) bilo kojeg tipa ili geneze uključivo, npr. aluminozu, antrakozu, azbestozu, kalikozu, ptilozu, siderozu, silikozu, tabakozu i bis-sinozu.
The ozone sanitizing system of claim 1, further comprising an exhaust port on the mask compartment. 
Uređaj CPAP (105) u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima ispušni izlaz na odjeljku maske (116).
The corresponding antagonists, where component (c) is provided, are preferably used in a quantity of ≥10 mg, particularly preferably in a quantity of 10 to 100 mg, very particularly preferably in a quantity of 10 to 50 mg per dosage form, i.e. per administration unit. 
Ako je predviđeno prisustvo komponente (c), odgovarajući antagonisti primjenjuju se prvenstveno u količini >1 mg, osobito pogodno u količini od 3 do 100 mg, a naročito pogodno u količini od 5 do 50 mg po obliku davanja, to znači po jedinici doziranja.
A method according to the previous paragraph further characterised in that the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6 mcg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content. 
Metoda prema patentnom zahtjevu 16 ili 17 dalje naznačeno time da je činjenica da je ukupna razina degradacijskog produkta formoterola niža od 2% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 95% w/w prema njegovom početnom sadržaju.
A method according to claim 33, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože i srca.
The method of controlling phytopathogenic fungi of agricultural crops comprising applying an effective amount to said agricultural crops of a fungicidal composition according to claim 1 for the control of phytopathogenic fungi belonging to the group of Basidiomycetes, Ascomycetes, Deuteromycetes or fungi imperfecti, Oomycetes: Puccinia spp., Ustilago spp., Tilletia spp., Uromyces spp., Phakopsora spp., Rhizoctonia spp., Erysiphe spp., Sphaerotheca spp., Podosphaera spp., Uncinula spp., Helminthosporium spp., Rhynchosporium spp., Pyrenophora spp., Monilinia spp., Sclerotinia spp., Septoria spp. 
Upotreba pripravaka u skladu s bilo kojim od patentnih zahtjeva od 8 do 10, naznačena time što su pripravci namijenjeni suzbijanju fitopatogenih gljivica koje pripadaju u skupine bazidiomiceti, askomiceti, Deuteromycetes ili fungi imperfecti, oomiceti: Puccinia spp., Ustilago spp., Tilletia spp., Uromyces spp., Phakopsora spp., Rhizoctonia spp., Erysiphe spp., Sphaerotheca spp., Podosphaera spp., Uncinula spp., Helminthosporium spp., Rhynchosporium spp., Pirenophora spp., Monilinia spp., Sclerotinia spp., Septoria spp.
The assembled cup body 12 then has an internal coating of polyethylene over all or a portion of its internal surface. 
Sklopljena čaša 12 ima tada unutarnju oblogu 15 od polietilena po cijeloj unutarnjoj površini ili na dijelu svoje unutarnje površine.
The cosmetic method according to claim 8, wherein the aging of the skin is caused by the exposure of the skin to the sun's rays. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je stanično starenje posljedica izlaganja kože suncu.
The pharmaceutical composition for use according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg of (11B,17B)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one. 
Farmaceutski pripravak za uporabu prema zahtjevu 1 naznačen time što farmaceutski pripravak sadrži oko 1 do 4 mg (11B,17B)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona.
23'. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the specific binding agent of item 22'. 
Farmaceutski pripravak koji se sastoji od farmaceutski prihvatljivog nositelja 1 terapeutski učinkovite količine antitijela ili antigen vezujućeg fragmenta istog prema jednom od zahtjeva 1 do 13.
The method as recited in claim 8, wherein the rubber layer (3) is an ordinary rubber layer or a foamed rubber layer; after vulcanization, an external surface of the rubber layer forms a layer of dense rubber membrane. 
Postupak prema zahtjevu 6, naznačen time, da gumeni sloj (3) je sloj od pjenaste gume; te nakon vulkanizacije, vanjska površina gumenog sloja stvara sloj guste gumene membrane.
Among them, a compound in which RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group is preferred. 
R gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom, halogenalkoksi skupinom, alkilendioksi skupinom, alkilenoksi skupinom ili mono- ili di-alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom ili halogenalkoksi skupinom; a R* je atom vodika;
The method according to any one of claims 6 to 17, wherein the number of oil droplets having a size of > 1.2 µm in the second emulsion is 5 x 1010 /ml or less. 
Postupak prema bilo kojem od zahtjeva 6 do 17, naznačen time da je broj kapljica ulja veličine > 1.2 um u drugoj emulziji 5 x 10/! /mlili manji.
The composition according to claim 26, wherein the beta2-adrenoceptor agonist is selected from enantiomerically pure or enantiomerically enriched R-enantiomer of Amiterol, Bamethan, Bitolterol, Butaxamine, Carbuterol, Cimaterol, Colterol, Clenbuterol, Clorprenaline, Colterol, Deterenol, Dioxethedrin, Etafedrine, Ethylnorepinephrine, Fenoterol, Indacaterol, Isoproterenol, Mabuterol, Meluadrine, Nardeterol, Norbudrine, Norepinephrine, Orciprenaline, Picumeterol, Pirbuterol, Quinprenaline, Reproterol, Salbutamol, Salmeterol, Soterenol, Sulfonterol, Terbutaline, Tulobuterol, Zinterol, a physiologically acceptable derivative thereof and a pharmaceutically acceptable salt thereof. 
Pripravak prema zahtjevu 18, naznačen time da je agonist beta2-adrenoceptora odabran od enantiomerno čistog ili enantiomerno obogaćenog R-enantiomera od Amiterola, Bametana, Bitolterola, Butaksamina, Karbuterola, Cimaterola, Kolterola, -Klenbuterola, Klorprenalina, Kolterola, Deterenola, Dioksetedrina, Etafedrina, Ftilnorepinefrina, Fenoterola, Indakaterola, Izoproterenola, Mabuterola, Meluadrina, Nardeterola, Norbudrina, Norepinefrina, Orciprenalina, Pikumeterola, Pirbuterola, Kvinprenalina, Reproterola, Salbutamola, Salmeterola, Soterenola, Sulfonterola, Terbutalinea, Tulobuterola, Zinterola, i njegova farmaceutski prihvatljiva sol. .
The antibody for use according to claim 15, wherein said in vivo detection comprises positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging or magnetic resonance imaging (MRI), and/or wherein the antibody is designed for use in the method of claim 14. 
Antitijelo za uporabu u skladu s patentnim zahtjevom 15, naznačeno time, da navedena in vivo detekcija sadržava pozitronsku emisijsku tomografiju (PET), tomografiju emisijom jednog fotona (SPECT), optičko snimanje u blizini infracrvenog spektra (NIR) ili magnetsku rezonanciju (MRI) 1 / ili pri čemu je antitijelo pripravljeno za upotrebu u postupku u skladu s patentnim zahtjevom 14.
R3, R4 and R8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", -SO2NR'R", -SO2R', nitro and trifluoromethyl; 
, R4 i R8, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika, alkoksi-skupina koja ima od jednoga do tri atoma ugljika, atom halogena, -OH,
The method of claim 1, wherein the polyclonal protein is a multimeric protein. The method of claim 15, wherein one expression vector encodes all subunits of one distinct polyclonal protein member. The method of claim 15, wherein the set of expression vectors in step a) comprises two or more subsets of expression vectors, where a first subset comprises nucleic acid sequences encoding one subunit of the multimeric protein, and a second subset comprises nucleic acid sequences encoding another subunit of the multimeric protein, such that each transfection is performed with a member of the first subset and a member of the second subset of expression vectors. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poliklonski protein je multimerni protein, primjerice kada jedan ekspresijski vektor kodira sve podjedinice jednog posebnog člana poliklonskog proteina, ili gdje skup ekspresijskih vektora u koraku a) čine dva ili više podskupova ekspresijskih vektora, gdje prvi podskup čine varijante sljedova nukleinskih kiselina koji kodiraju jednu podjedinicu proteina, primjerice teški lanac protutijela, a drugi podskup čine varijante sljedova nukleinskih kiselina koji kodiraju drugu podjedinicu proteina, primjerice laki lanac protutijela, tako da se svako transficiranje provodi članom prvog podskupa i članom drugog podskupa ekspresijskih vektora.
The receiver of claim 5, further comprising: a time-frequency deinterleaver (r709-L1, r710-L1) configured to time-frequency deinterleave constellation values corresponding to PLP data; 
Prijamnik iz patentnog zahtjeva 5, nadalje obuhvaća: dio za raspletanje vremena-frekvencije (r709-L1, r710-L1) podešen za raspletanje konstelacijskih vrijednosti vremena-frekvencije u skladu s PLP podacima;
providing irbesartan having a maximum particle diameter of not more than 2000 µm, (ii') mixing the irbesartan and one or more excipient(s) to give compression mixture, and 
(i) pribavljanje irbesartan hidroklorida čiji najveći promjer čestice nije veći od 2000 um, (il) miješanje irbesartan hidroklorida i jedne ili više pomoćnih tvari da bi se dobila smjesa za komprimiranje, te
A hydrogen sulfate salt of Compound 1 according to claim 4, wherein said hydrogen sulfate salt of Compound 1 has an X-ray powder diffraction pattern with at least one specific peak at about 24.59°. 
Sol hidrogen sulfata od Spoja 1 prema zahtjevu 4, gdje ta hidrogen sulfatna sol Spoja 1 ima obrazac rendgenskog zračenja praha s barem jednim specifičnim pikom na oko 24.59".
The formulation of claim 1, comprising the buffer, wherein the buffer is a phosphate salt. 
Formulacija lijeka s odloženim otpuštanjem sukladno jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer fosfatna sol.
Z is hydrogen only when Y is a covalent bond and X is optionally substituted 1,4-pyrazolene attached to the purine ring by a carbon atom; and 
Z je vodik samo kada je Y kovalentna veza i X je opcijski supstituirani 1,4-pirazolen vezan za purinski prsten sa atomom ugljika; i
hydrolyzing a compound of formula (VII) to obtain a compound of formula (I). 
(v) hidroliza spoja formule (VII) pri čemu nastaje spoj formule (I).
A mucoadhesive drug delivery device suitable for direct transmucosal administration of an effective amount of buprenorphine to a subject, the device comprising; 
Mukoadhezivna terapijska naprava pogodna za izravnu transmukoznu primjenu učinkovite količine buprenorfina subjektu, naprava obuhvaća:
In WO 95/01471 there is described a process for producing soil-repellant and abrasion-resistant monofilaments for screen cloth having a diameter from 0.1 to 1.0 mm from a linear silicon modified polyethylene terephthalate. 
U WO 95/01471 opisan je proces za proizvodnju monofilamcnata otpornih na vlagu i abraziju, za zaštitno platno promjera od 0.1 do 1.0 mm, od linearnog polietilen tereftalata modificiranog silikonom.
Process according to any of claims 1 to 9, characterized in that step c) is carried out at pH 7. 
Postupak prema bilo kojem zahtjevu od 1 do 14, naznačen time da se sredstvo za blokiranje slobodnog lantanida, poželjno polikarboksilna kiselina, dodaje u koraku b).
All percentages reported herein, unless otherwise specified, are percent by weight. 
Svi postotci koji su ovdje navedeni, ako nije drukčije specificirano, su maseni postotci.
This invention relates to novel diketopiperazine derivatives having a potent and selective antagonist action at the oxytocin receptor, to processes for their preparation, pharmaceutical compositions containing them and to their use in medicine. 
Ovaj izum odnosi se na nove diketopiperazinske derivate s potentnim i selektivnim antagonističkim djelovanjem na oksitocinski receptor, na postupke njihovog dobivanja, farmaceutske pripravci koji ih sadrže, te na njihovu upotrebu u medicini.
Intermediate 11: (R)-7-(2-(3-fluoropyrrolidin-3-yl)ethyl)-1,2,3,4-tetrahydro-1,8-naphthyridine 
(3-(2-metoksietoksi)fenil)butanska kiselina; ili njezina farmaceutski prihvatljiva sol.
wherein said replication-defective recombinant Adenovirus is a priming composition and said adjuvated proteinaceous antigen is a boosting composition.. 
gdje navedeni replikacijski deficijentni rekombinantni adenovirus je inicijalni pripravak, a navedeni adjuvantirani proteinski antigen je pojačivački pripravak.
Description of embodiments of the invention 
Broj objave europskog patenta:
The method of claim 25, wherein therapeutically effective amount of Crenolanib or a salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed proliferative disease patient, to maintain remission, or a relapsed/refractory proliferative disease patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
The compound for use according to claim 1 or claim 2, wherein: 
Tvar za uporabu u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, pri čemu:
Apparatus for treating water at low cost, according to claim 1, wherein the receiving means is covered with a material comprising membranes, geo-membranes, geotextile membranes, plastic liners, concrete, or coated concrete, or a combination thereof. 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što se informacije koje primaju koordinacijska sredstva dobivaju vizualnim pregledom, algoritmima koji se temelje na iskustvu, elektronskim detektorima ili njihovim kombinacijama.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3 preferably equal to or less than about 1.19 g/cm3. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
In a further aspect provided herein, an antibody binds to the same epitope as an anti-FcRH5 antibody provided herein. In certain embodiments, an antibody is provided that binds an isoform c-specific region of the extracellular domain of FcRH5c from, within, or overlapping amino acids 754-835 of SEQ ID NO:1. 
HR P20180352 T1 PATENTNI ZAHTJEVI Izolirano protutijelo anti-FcRH5, naznačeno time, da veže izoformno c-specifično područje izvanstanične domene od FcRH5Se, prikazano kao aminokiseline 743-850 od SEQ ID NO: 1, pri čemu protutijelo ne veže značajno niti jednu drugu domenu od FcRH5, koja je nalik na Ig.
Embodiment 16 6-chloro-8-(1-methylhexyl-D15)-2-(trifluoromethyl)-2 H -chromene-3-carboxylic acid The synthetic method refers to Embodiment 1. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6,8-dibromo-5,7-(dimetil -D6)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
wherein (n) is an integer from 2 to about 4000, and unreacted disuccinimidyl carbonate; 
HR P20150247 T1 pri čemu (n) je cijeli broj od 2 do 4000, i neizreagirani p-nitrofenil kloroformat;
The methanol is removed in vacuo and the resulting white suspension is extracted with chloroform (3×20 ml), dried (MgS04) and concentrated in vacuo to yield a white powder which is dried under high vacuum to yield the titled product. 
Metanol se odstrani u vakuumu i dobivenu bijelu suspenziju se ekstrahira s kloroformom (3 x 20 ml), osuši (MgSOxy) i koncentrira u vakuumu, čime se dobije bijeli prah koji se osuši pod visokim vakuumom, čime se dobije naslovni proizvod.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
An antibody according to claim 1 wherein the variable domain of the heavy chain comprises sequence SEQ ID NO: 5, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto. 
Protutijelo prema bilo kojem od zahtjeva 1 do 9, naznačeno time da sadrži: varijabilnu domenu teškog lanca od sekvence SEQ ID NO:31 ili sekvencu koja je s njom barem 85% identična i/ili varijabilnu domenu lakog lanca od sekvence SEQ ID NO:32, ili sekvencu koja je s njom barem 85% identična; ili
Heavy chain CDRs: SEQ ID NO: 4, 5 and 6, or a functional fragment or analogue thereof, wherein said antibody, functional fragment or analogue thereof binds to and neutralises human NogoA. 
CDR-e teških lanaca: SEQID NO: 4,516, ili njegov funkcionalni fragment ili analog, gdje navedeno protutijelo, njegov funkcionalni fragment ili analog, se veže na i neutralizira ljudski Nogo-A.
Use of the compound as claimed in any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof, or a solvate thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic diseases and chronic myeloproliferative disease. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
Composition according to any of claims 1 to 10, characterised in that it comprises a sweetener chosen from the group formed by sodium saccharin, calcium saccharin, sucralose, aspartame, acesulfame potassium, sodium or potassium cyclamate, neohesperidin dihydrochalcone, thaumatin and their mixtures. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što sadrži sladilo, koje se bira iz skupine koju čine saharin-natrij, saharin-kalcij, sukraloza, aspartam, acesulfam-kalij, natrijev ili kalijev ciklamat, neohesperidin dihidročalkon, taumatin i njihove smjese.
The process of claim 7, wherein cyclizing comprises heating the trans-amino acid derivative of formula I or formula II in a solvent and in the presence of sodium acetate. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se ciklizacija sastoji u grijanju transaminokiselinskog derivata formule 1 ili formule II u otapalu i u prisutnosti natrijevog acetata.
System as claimed in claim 1, characterized in that said first (D1) and said second series of data (D2) are digital, said first communication means (5) and said second communication means (12) being chosen between the group comprising the Ethernet communication standards, wireless communication standards, Bluetooth or similar communication standards. 
Sistem u skladu sa patentnim zahtjevom 1, naznačen time da su navedena prva (D1) i navedena druga serija podataka (D2) digitalne, navedena prva sredstva za komunikaciju (5) i navedena druga sredstva za komunikaciju (12) su izabrana između grupe koja sadrži komunikacijske standarde Eterneta, bežične komunikacijske standarde, „Bluetooth“ ili slične komunikacijske standarde.